Serious complications due to blood clots, such as heart attacks and strokes, experienced by some COVID-19 survivors may be caused by a lingering immune response in the blood vessels after recovery, suggests a study published today in eLife.
The findings may help explain why some COVID-19 survivors, so-called ‘long-haulers’, report lasting COVID-19 symptoms or why some experience strokes or heart attacks weeks or months after recovery. They may also suggest potential strategies to help prevent these complications.
“During the initial stages of infection, SARS-CoV-2, the virus that causes COVID-19, may attack the lining of the blood vessels which can trigger inflammation and an immune response. This can result in blood vessel damage in the short term,” explains first author Florence Chioh, Research Assistant at the Lee Kong Chian School of Medicine (LKCMedicine), Nanyang Technological University, Singapore. “For our study, we wanted to investigate what happens in the blood vessels of COVID-19 survivors over the longer term.”
Chioh and colleagues collected blood samples from COVID-19 survivors within a month of their recovery and discharge from the hospital. They found that, in comparison with healthy individuals, COVID-19 survivors have twice as many damaged blood vessel cells, called circulating endothelial cells, floating in their blood. Even more of these damaged blood vessel cells were found in survivors who had conditions such as hypertension or diabetes that can also damage the blood vessels.
In addition to signs of blood vessel damage, the team found that survivors had an abundance of inflammatory proteins called cytokines that are produced by immune cells. They also found unusually high numbers of immune cells called T cells, which help destroy viruses, despite the fact that the virus was already gone.
“We show that an overactive immune system is the likely cause of blood vessel damage seen in some COVID-19 survivors,” Chioh says. “This may cause ‘leakiness’ in the blood vessels that increases the risk of blood clots.”
“Our work suggests that COVID-19 patients, especially those with underlying chronic conditions, may benefit from close post-recovery monitoring,” adds senior author Christine Cheung, Assistant Professor and Provost’s Chair in Medicine at LKCMedicine. “This would help identify high-risk individuals who may need blood thinners or preventative therapy to protect them from debilitating blood-clotting complications.”
eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Cell Biology and Immunology and Inflammation, while exploring creative new ways to improve how research is assessed and published. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
To read the latest Cell Biology research published in eLife, visit https://elifesciences.org/subjects/cell-biology.
And for the latest in Immunology and Inflammation, see https://elifesciences.org/subjects/immunology-inflammation.